Skip to main content
S&P 5007,803.03-0.20%DOW51,234.59-0.56%NASDAQ27,498.81-0.37%BTC$83,247.00-2.73%ETH$2,560.04-5.02%GOLD$4,145.40-1.00%OIL$88.36-1.21%
Smart Investors Daily
SID Premium
IN

NASDAQ · INMB

INmune Bio, Inc.

Healthcare · Biotechnology

$1.87

Down-$0.02 (-0.80%)

Updated Oct 7, 2026, 3:26 PM

SID Score

5.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
56.63M
P/E ratio
-1.14
Dividend yield
0.00%
52-week range
$1.09 – $2.60
Volume
311.07K
Avg. volume
455.95K

Price performance · INMB

INMB price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

INMB closed at $1.87 after 21 trading sessions, down 25.50% for the selected period.

Last close
$1.87
Period change
-25.50%
Period low
$1.87
Period high
$2.51
Daily close
View OHLC price history
INMB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$1.95$1.9775$1.82$1.87311.07K
Oct 5, 2026$1.90$1.97$1.88$1.94267.25K
Oct 2, 2026$1.97$1.9987$1.93$1.93290.24K
Oct 1, 2026$1.96$1.97$1.88$1.93340.81K
Sep 30, 2026$1.98$2.02$1.94$1.95201.9K
Sep 29, 2026$2.01$2.02$1.94$1.96286.55K
Sep 28, 2026$2.02$2.045$1.94$2.00191.6K
Sep 25, 2026$2.01$2.04$1.96$2.03196.17K
Sep 24, 2026$2.00$2.01$1.94$2.00167.87K
Sep 23, 2026$2.15$2.175$1.99$2.00487.6K
Sep 22, 2026$2.31$2.36$2.16$2.16375.46K
Sep 21, 2026$2.35$2.4199$2.29$2.29306.67K
Sep 18, 2026$2.22$2.3976$2.213$2.33677.64K
Sep 17, 2026$2.065$2.215$2.06$2.18421.67K
Sep 16, 2026$2.22$2.2384$1.965$2.05923.29K
Sep 15, 2026$2.35$2.35$2.21$2.26350.25K
Sep 14, 2026$2.23$2.35$2.18$2.33370.1K
Sep 11, 2026$2.35$2.37$2.21$2.22228.38K
Sep 10, 2026$2.43$2.46$2.29$2.31385.85K
Sep 9, 2026$2.545$2.575$2.45$2.46239.84K
Sep 8, 2026$2.44$2.60$2.41$2.51494.31K

Latest INMB news

The latest Smart Investors Daily articles mentioning INMB.

Stock researchCompany · Overview

INMB research

Overview

Company profile and research snapshot.

Company profile

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$22.00
Implied upside
—
Analysts
—
INMB recent ratings
DateFirmRatingTarget
Mar 11, 2026LUCID CAPITAL MARKETSBuy—
Jul 2, 2025Maxim GroupBuy—
Jul 1, 2025ScotiabankSector Underperform—
Jul 1, 2025BTIGNeutral—
Feb 13, 2025Maxim GroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 14, 2026

INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board

Appointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization BOCA RATON, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced the appointments of R. Duane Clark II and James Sapirstein, R.Ph., MBA, to its Board of Directors. The appointments add commercial and strategic ope

Yahoo · Sep 9, 2026

INmune Bio to Present at the H.C. Wainwright Global Investment Conference

The on-demand presentation will be available on September 11, 2026, at 7:00 A.M. (ET) BOCA RATON, Fla, Sept. 09, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced their attendance at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16 at the Lotte New York Palace Hotel in New York City. David Moss, Founder and Chief Executive Officer, will be ho

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By